Aspire Biopharma Holdings (ASBP) Return on Assets (2025 - 2026)
Aspire Biopharma Holdings (ASBP) posted quarterly Return on Assets of 0.03% for Q1 2026, up 13.0% year-over-year from 0.03% in Q1 2025, and up 76.96% quarter-over-quarter from 0.14% in Q4 2025.
Aspire Biopharma Holdings (ASBP) Return on Assets (2025 - 2026) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has reported Return on Assets for 2 consecutive years, with 0.03% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Assets rose 13.0% year-over-year to 0.03%; the TTM figure through Mar 2026 stood at 0.03% (up 13.0% YoY), while the FY2025 annual figure was 0.26%, down 26.0% from the prior year.
- Return on Assets rose to 0.03% in Q1 2026 per ASBP's latest filing, from 0.14% in the prior quarter.
- Across five years, Return on Assets topped out at 0.03% in Q1 2026 and bottomed at 0.16% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 0.00% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 0.00% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 0.00% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 0.00% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 0.00% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 0.00% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 0.00% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 0.00% |
| 10 | Aspire Biopharma Holdings | 8.30 Mn | -3.86 Mn | -30,086.00 | -0.01% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.01% |
| Mar 31, 2026 | -0.03% |
| Dec 31, 2025 | -0.14% |
| Sep 30, 2025 | -0.11% |
| Jun 30, 2025 | -0.11% |
| Mar 31, 2025 | -0.16% |